Target intelligence / Profile preview

CHD2-adjacent suppressive epitranscriptomic regulatory RNA (CHASERR) (CHASERR)

Target
CHASERR
Molecular classification
Other, Regulatory RNA, Long non-coding RNA
01

Overview

CHASERR (CHD2-adjacent suppressive epitranscriptomic regulatory RNA), also known as LINC01578, is a long non-coding RNA (lncRNA) transcribed from a region immediately upstream of the Chromodomain Helicase DNA Binding Protein 2 (CHD2) gene (Rom et al., 2019, Nature Communications). It functions as a highly conserved cis-regulator that maintains CHD2 homeostasis by suppressing its transcription; loss of CHASERR leads to a significant increase in CHD2 levels (NCBI Gene, 2024). In humans, CHD2 haploinsufficiency is a known cause of severe neurodevelopmental disorders, including Dravet-like syndrome, Lennox-Gastaut syndrome, and autism spectrum disorder (Suls et al., 2013, American Journal of Human Genetics). Because CHASERR naturally limits CHD2 expression, it has emerged as a promising therapeutic target for these conditions. Experimental strategies using antisense oligonucleotides (ASOs) to knock down CHASERR have demonstrated the ability to upregulate the remaining functional CHD2 allele, potentially restoring protein levels to a physiological range (Ionis Pharmaceuticals, 2023). This mechanism offers a potential disease-modifying treatment for patients with CHD2-deficient encephalopathies.

Other names
LINC01578Long intergenic non-protein coding RNA 1578CHD2-AS1CHD2-adjacent suppressive epitranscriptomic regulatory RNA
02

Mechanism of action

Knockdown of CHASERR lncRNA using antisense oligonucleotides to relieve the repression of the CHD2 gene, thereby increasing CHD2 protein levels.

03

Biological functions

OtherGene expression regulationTranscriptional repressionCis-regulation
04

Disease associations

OtherNeurodevelopmental diseaseEpilepsyAutism spectrum disorderIntellectual disability
05

Safety considerations

CHD2 overexpression toxicityOff-target RNA bindingAntisense oligonucleotide-related neurotoxicityCentral nervous system delivery challenges
06

Interacting drugs

Antisense oligonucleotides
07

Biomarkers

CHD2 mRNA levelsCHD2 protein levelsCHASERR RNA expression levels

Beyond the preview

Go deeper on CHD2-adjacent suppressive epitranscriptomic regulatory RNA (CHASERR) (CHASERR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHD2-adjacent suppressive epitranscriptomic regulatory RNA (CHASERR) (CHASERR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call